Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies
William J. Sandborn(University of San Diego), M. Scott Harris(Altimmune (United States)), Michael Safdi(University of Chicago), M. Edeline(Marietta College), S. B. Hanauer(University of Chicago), Gary R. Lichtenstein(University of Pennsylvania)
Cited by 30
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
|New England Journal of Medicine|2012|794